We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

38 hedge funds and large institutions have $85.1M invested in CTI BioPharma Corp. (DE) Common Stock in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

343% more call options, than puts

Call options by funds: $541K | Put options by funds: $122K

113% more capital invested

Capital invested by funds: $40M → $85.1M (+$45.1M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

12% less funds holding

Funds holding: 43 → 38 (-5)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

Holders
38
Holders Change
-5
Holders Change %
-11.63%
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
5
Increased
10
Reduced
8
Closed
10
Calls
$541K
Puts
$122K
Net Calls
+$419K
Net Calls Change
+$385K

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$4.72M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$984K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$877K
4
Two Sigma Investments
Two Sigma Investments
New York
+$176K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$166K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$383K
2
Millennium Management
Millennium Management
New York
-$71K
3
PP
Paloma Partners
Connecticut
-$35K
4
UBS Group
UBS Group
Switzerland
-$26.8K
5
HF
HRT Financial
New York
-$22K

CTIC Hedge Fund Activity: Q3 2020 in Review

38 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2020, worth a combined $85.1M — up 113% from $40M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CTIC and 5 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 10 added.

The largest buyer was Caxton Corporation, adding an estimated $4.72M. The largest seller was Stonepine Capital Management, cutting an estimated $383K.

  • 38 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2020, down from 43 in Q2 2020.
  • Funds reported $85.1M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2020, up 113% quarter-over-quarter.
  • 5 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2020 and 10 closed out, a net change of -5 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2020 was Caxton Corporation, an estimated $4.72M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2020 was Stonepine Capital Management, an estimated $383K sold.

Based on aggregated 13F filings for Q3 2020.